

Cytosorbents Corp  
Form 8-K  
December 08, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): December 5, 2014

**CYTOSORBENTS CORPORATION**

(Exact name of registrant as specified in its charter)

<b>Delaware</b>	<b>000-51038</b>	<b>98-0373793</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

**7 Deer Park Drive, Suite K,**

**Monmouth Junction, New Jersey 08852**  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(732) 329-8885**

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

As previously announced, on December 3, 2014, CytoSorbents Corporation (the “Company”) effected a twenty-five-for-one (25:1) reverse split of its common stock and a merger with and into its recently formed, wholly-owned Delaware subsidiary. Beginning on December 5, 2014, after giving effect to such corporate actions, the Company’s common stock began trading on the OTCQB Marketplace under the symbol “CTSOD”, which shall remain for 20 business days until on or about January 4, 2015, after which the symbol will revert back to “CTSO”.

A copy of the press release announcing the change in trading symbol is attached hereto as Exhibit 99.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit No. Description**

99	Press Release of the Company, dated December 5, 2014.
----	---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 8, 2014      CYTOSORBENTS  
CORPORATION

By:    /s/ Dr. Phillip P. Chan  
Name: Dr. Phillip P. Chan  
      President and  
Title:  
      Chief Executive Officer